None of the 29 investors followed here reported a position in ICUI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | 1 | −$8.0K | Trimmed May 6, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| May 6, 25 | Gilbert Cisneros CA31 | Self | Sell (part) | $1,001 - $15,000 | Jun 6, 25 (31d) |
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Sanzone Virginia RuthGeneral Counsel | Sale at price 167.67 - 171.52 per share. | 4.9K | $819.15K |
| Aug 31, 2026 | Bonnell Brian MichaelChief Financial Officer | Sale at price 175.00 per share. | 6.4K | $1.12M |
| Aug 30, 2026 | Bonnell Brian MichaelChief Financial Officer | Sale at price 171.05 - 173.91 per share. | 9.3K | $1.61M |
| Aug 12, 2026 | Woolson DanielOfficer | Sale at price 181.33 per share. | 5.4K | $982.26K |
| Aug 11, 2026 | Sousa BenChief Technology Officer | Sale at price 178.32 per share. | 2.3K | $401.21K |
| Aug 10, 2026 | Voigtlander Christian BChief Operating Officer | Sale at price 182.93 per share. | 8.9K | $1.63M |
| Aug 10, 2026 | Finney Elisha WDirector | Sale at price 182.48 per share. | 378 | $68.98K |
| May 21, 2026 | Woolson DanielPresident | Sale at price 132.21 per share. | 2.1K | $280.69K |
| May 13, 2026 | Sanzone Virginia RuthGeneral Counsel | Sale at price 124.08 per share. | 2.4K | $303.62K |
| May 12, 2026 | Hernandez LaurieDirector | — | 1.3K | — |
| May 12, 2026 | Kennedy Kolleen TDirector | — | 1.3K | — |
| May 12, 2026 | Greenberg David CDirector | Conversion of Exercise of derivative security at price 101.06 per share. | 3.7K | $244.97K |
| May 12, 2026 | Finney Elisha WDirector | — | 1.3K | — |
| May 12, 2026 | Abbey Donald MDirector | — | 1.3K | — |
| May 12, 2026 | Hoffmeister David FDirector | — | 1.3K | — |
| May 11, 2026 | Greenberg David CDirector | Sale at price 122.91 per share. | 2.4K | $297.93K |
| Mar 12, 2026 | Woolson DanielOfficer | — | 2.9K | — |
| Mar 12, 2026 | Bonnell Brian MichaelChief Financial Officer | — | 14.6K | — |
| Mar 12, 2026 | Sousa BenChief Technology Officer | — | 1.3K | — |
| Mar 12, 2026 | Jain VivekChief Executive Officer | — | 22K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.1 | 0.5 | -14.2 | -7.7 | 13.6 | 8.3 | 14.9 | 2.6 | -7.2 | 2.1 | +14.9% | ||
| 2025 | 5.9 | -11.0 | -5.1 | -1.6 | -1.3 | -2.0 | -2.8 | -0.6 | -6.0 | 0.1 | 23.6 | -3.9 | −8.1% |
| 2024 | -8.2 | 19.3 | -1.7 | -8.8 | 8.6 | 11.7 | 6.9 | 30.2 | 10.2 | -6.3 | -4.0 | -5.4 | +55.6% |
| 2023 | 22.7 | -11.7 | -3.3 | 14.7 | -7.5 | 1.9 | -0.0 | -18.6 | -17.9 | -17.6 | -10.5 | 13.7 | −36.7% |
| 2022 | -10.1 | 11.0 | -6.0 | -3.9 | -15.1 | -9.5 | 7.8 | -10.3 | -5.3 | -1.5 | 7.3 | -1.1 | −33.6% |
| 2021 | -4.7 | 1.5 | -1.0 | 1.4 | -0.1 | -1.1 | -1.2 | -1.9 | 17.1 | 0.3 | -3.4 | 4.9 | +10.7% |
| 2020 | -2.5 | 7.3 | 3.0 | 8.7 | -9.0 | -7.7 | -0.3 | 9.0 | -8.7 | -2.7 | 6.1 | 13.7 | +14.6% |
| 2019 | 8.3 | -1.2 | -2.6 | -4.9 | -6.5 | 18.4 | 1.0 | -36.4 | -1.3 | 1.3 | 16.0 | -0.2 | −18.5% |
| 2018 | 6.0 | 1.0 | 9.1 | -0.3 | 15.6 | 0.9 | -2.3 | 6.7 | -7.6 | -9.9 | -5.6 | -4.5 | +6.3% |
| 2017 | -7.0 | 9.7 | 1.5 | 0.7 | 4.9 | 6.9 | -0.3 | 1.4 | 6.6 | 2.8 | 11.7 | 1.2 | +46.6% |
| 2016 | -14.7 | -4.5 | 13.3 | -4.6 | 4.7 | 8.4 | 3.6 | 6.9 | 1.3 | 10.2 | 7.9 | -1.9 | +30.7% |
| 2015 | 2.1 | 6.4 | 4.8 | -9.4 | 15.0 | -1.4 | 4.5 | 13.6 | -3.5 | 0.4 | 3.2 | -0.6 | +37.7% |
| 2014 | 1.3 | -10.3 | 3.5 | -6.8 | 7.7 | 1.2 | -4.2 | 7.5 | 2.5 | 10.5 | 18.0 | -2.1 | +28.6% |
| 2013 | -0.8 | -6.1 | 3.9 | 2.2 | 18.5 | 0.9 | -0.5 | -0.3 | -5.0 | -9.0 | 6.3 | -3.0 | +4.6% |
| 2012 | 3.3 | -1.3 | 7.1 | 6.8 | -2.0 | 3.8 | -0.1 | 4.1 | 9.0 | -2.1 | -0.5 | 3.5 | +35.4% |
| 2011 | 7.0 | 7.5 | 4.3 | 3.0 | -3.9 | 0.8 | -2.8 | -3.0 | -10.7 | 6.8 | 12.0 | 2.2 | +23.3% |
| 2010 | -4.6 | -1.2 | 0.2 | 3.4 | -10.6 | 1.1 | 15.7 | -4.3 | 4.7 | -2.1 | 0.4 | -0.4 | +0.2% |
| 2009 | -7.9 | 3.3 | 1.9 | 17.1 | -3.8 | 13.8 | -5.4 | -4.5 | -0.9 | -5.0 | -5.7 | 10.4 | +10.0% |
| 2008 | -21.2 | -5.5 | 7.2 | -12.7 | 1.4 | -10.2 | 24.3 | 6.8 | 0.1 | 5.3 | -5.6 | 9.6 | −8.0% |
| 2007 | -3.0 | -1.0 | 0.4 | 6.5 | -3.8 | 6.9 | -22.6 | 13.7 | 2.5 | 3.5 | -7.4 | -3.0 | −11.5% |
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Buy / hold / sell counts